Former football players demand that the NFL reconsider the league’s current policy on marijuana and take part in a study that may prove medical cannabis is beneficial for players. SportDailyTimes will provide you with the most significant reasons behind that demand.

It is not a secret that American football is quite a tough game. There are tons of various traumas and injuries in the lives of most of the professional football players. So, in order to stay on the field, they are literally forced to use a combination of strong painkillers with dozens of side effects. Passion for the game costs them their health and well-being while there may be a possibility to keep playing without harming both their minds and bodies.

Medical marijuana may help football players deal with injuries and illnesses caused by traumas they received on the field. Medical cannabis is believed to be an efficient yet more safe alternative to prescription painkillers. We have 23 states with legalized medical cannabis, and the number of the states with legalized recreational weed continues to grow. This year, there may be a few more states added to the list.

When people started to speak openly about the possibilities they get from using marijuana as a medicine, the former NFL players joined the discussion and stated the need to change the marijuana policy within the league.

Nowadays people usually connect their fatigue with a hectic lifestyle. And in most cases, they are right. However, if you feel weak almost all the time, do not neglect it. Take several weeks to change your lifestyle for a while: eat more better-for-you foods, sleep more at night, drink more water, take the necessary vitamins, and reduce consumption of alcohol and coffee. If chronic tiredness syndrome remains after those changes, then you should ask for professional advice. Your weakness may be a symptom of some chronic medical conditions that should be identified and treated.  

Below you will find five most common reasons for fatigue that may not have crossed your mind.

In a paper published last month in the SIAM Journal on Applied Mathematics, authors Sean McGinty, Sean McKee, Roger Wadsworth, and Christopher McCormick devise a mathematical model to improve currently-employed treatments of coronary heart disease (CHD).

"CHD remains the leading global cause of death, and mathematical modeling has a crucial role to play in the development of practical and effective treatments for this disease," says lead author Sean McGinty. "The use of mathematics allows often highly complex biological processes and treatment responses to be simplified and written in terms of equations which describe the key parameters of the system. The solution of these equations invariably provides invaluable insight and understanding that will be crucial to the development of better treatments for patients in the future."

The accumulation of plaque during CHD can result in chest pain, and ultimately, rupture of the artherosclerotic plaque, which causes blood clots blocking the artery and leading to heart attacks. A common method of treatment involves inserting a small metallic cage called a stent into the occluded artery to maintain blood flow.

However, upon insertion of a stent, the endothelium—the thin layer of cells that lines the inner surface of the artery—can be severely damaged. The inflammatory response triggered as a result of this damage leads to excessive proliferation and migration of smooth muscle cells (cells in the arterial wall that are involved in physiology and pathology) leading to re-blocking of the artery. This is an important limitation in the use of stents. One way to combat this has been the use of stents that release drugs to inhibit the smooth muscle cell proliferation, which causes the occlusion. However, these drug-eluting stents have been associated with incomplete healing of the artery. Studies are now being conducted to improve their performance.

"Historically, stent manufacturers have predominantly used empirical methods to design their drug-eluting stents. Those stents which show promising results in laboratory and clinical trials are retained and those that do not are discarded," explains McGinty. "However, a natural question to ask is, what is the optimal design of a drug-eluting stent?"

The design of drug-eluting stents is severely limited by lack of understanding of the factors governing their drug release and distribution. "How much drug should be coated on the stent? What type of drug should be used?" McGinty questions. "All of these issues, of course, are inter-related. By developing models of drug release and the subsequent uptake into arterial tissue for current drug-eluting stents, and comparing the model solution with experimental results, we can begin to answer these questions."

The model proposed by the authors considers a stent coated with a thin layer of polymer containing a drug, which is embedded in the arterial wall, and a porous region of smooth muscle cells embedded in an extracellular matrix.

When the polymer region and the tissue region are considered as a coupled system, it can be shown under certain conditions that the drug release concentration satisfies a special kind of integral equation called the Volterra integral equation, which can be solved numerically. The drug concentration in the system is determined from the solution of this integral equation. This gives the mass of drug within cells, which is of primary interest to clinicians.

The simple one-dimensional model proposed in the paper provides analytical solutions to this complex problem. "While the simplified one and two-dimensional models that our group and others have recently developed have provided qualitative results and useful insights into this problem, ultimately three-dimensional models which capture the full complex geometry of the stent and the arterial wall may be required," McGinty says.

In a complex environment with pulsating blood flow, wound healing, cell proliferation and migration, and drug uptake and binding, the process of drug release from the stent may involve a multitude of factors, which could be best understood by three-dimensional models. "This is especially relevant when we want to consider the drug distribution in diseased arteries and when assessing the performance of the latest stents within complex geometries, where for instance, the diseased artery may bifurcate," says McGinty. "We are therefore currently investigating the potential benefits of moving to three-dimensional models."